SR59230A,98.0%

产品编号:Bellancom-100672| CAS NO:174689-39-5| 分子式:C23H29NO6| 分子量:415.48

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-100672
1300.00 杭州 北京(现货)
Bellancom-100672
2200.00 杭州 北京(现货)
Bellancom-100672
8000.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

SR59230A

产品介绍 SR59230A 是一种有效,选择性的,可透过血脑屏障的 β3-肾上腺素能受体 (β3-adrenergic receptor) 拮抗剂,对 β3,β1 和 β2 受体的 IC50 分别为 40、408 和 648 nM。
生物活性

SR59230A is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist with IC50s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively.

体外研究

SR59230A (100 nM-50 μM; 24 hours) is able to reduce cell viability in a dose-dependent manner in Neuro-2A, BE(2)C and SK-N-BE(2) NB cell lines.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line: Three different neuroblastoma (NB) cell lines, one murine (Neuro-2A) and two human (SK-N-BE(2), BE(2)C)
Concentration: 100 nM, 1 μM, 5 μM, 10 μM, and 50 μM
Incubation Time: 24 hours
Result: Reduced cell viability in a dose-dependent manner, with significant effect at a concentration limit over 1 µM for Neuro-2A cells and 5 µM for SK-N-BE(2) and BE(2)C).
体内研究
(In Vivo)

MDMA (20 mg/kg) produces a slowly developing hyperthermia, reaching a maximum increase of 1.8°C at 130 min post injection. SR59230A (0.5 mg/kg) produces a small but significant attenuation of the slowly developing hyperthermia to MDMA. SR59230A (5 mg/kg) reveals a significant and marked early hypothermic reaction to MDMA[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male C-57BL6J wild-type mice (22-35 g)[4]
Dosage: 0.5 or 5 mg/kg
Administration: Injected s.c.; administered 30 min prior to the injection s.c. of MDMA (20 mg/kg).
Result: Modulated the actions of MDMA on temperature involve α1-adrenoceptor antagonism.
体内研究

MDMA (20 mg/kg) produces a slowly developing hyperthermia, reaching a maximum increase of 1.8°C at 130 min post injection. SR59230A (0.5 mg/kg) produces a small but significant attenuation of the slowly developing hyperthermia to MDMA. SR59230A (5 mg/kg) reveals a significant and marked early hypothermic reaction to MDMA[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male C-57BL6J wild-type mice (22-35 g)[4]
Dosage: 0.5 or 5 mg/kg
Administration: Injected s.c.; administered 30 min prior to the injection s.c. of MDMA (20 mg/kg).
Result: Modulated the actions of MDMA on temperature involve α1-adrenoceptor antagonism.
体内研究

MDMA (20 mg/kg) produces a slowly developing hyperthermia, reaching a maximum increase of 1.8°C at 130 min post injection. SR59230A (0.5 mg/kg) produces a small but significant attenuation of the slowly developing hyperthermia to MDMA. SR59230A (5 mg/kg) reveals a significant and marked early hypothermic reaction to MDMA[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male C-57BL6J wild-type mice (22-35 g)[4]
Dosage: 0.5 or 5 mg/kg
Administration: Injected s.c.; administered 30 min prior to the injection s.c. of MDMA (20 mg/kg).
Result: Modulated the actions of MDMA on temperature involve α1-adrenoceptor antagonism.
性状Solid
溶解性数据
In Vitro: 

DMSO : 31.25 mg/mL (75.21 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.4069 mL 12.0343 mL 24.0685 mL
5 mM 0.4814 mL 2.4069 mL 4.8137 mL
10 mM 0.2407 mL 1.2034 mL 2.4069 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (5.01 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.01 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液
  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (5.01 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.01 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (5.01 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.01 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 西域 网站选购。
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服